First-Line Dacomitinib versus Gefitinib in Advanced Non-Small-Cell Lung Cancer with EGFR Mutation Subgroups

被引：0

作者：

Wu, Y. ^{[1
,2
]}

Cheng, Y. ^{[3
]}

Zhou, X. ^{[4
]}

Lee, K. H. ^{[5
]}

Nakagawa, K. ^{[6
]}

Niho, S. ^{[7
]}

Tsuji, F. ^{[8
]}

Rosell, R. ^{[9
]}

Corral, J. ^{[10
]}

Migliorino, M. R. ^{[11
]}

Pluzanski, A. ^{[12
]}

Linke, R. ^{[13
]}

Sbar, E. ^{[14
]}

Wang, T. ^{[15
]}

Zhang, H. ^{[16
]}

Mok, T. ^{[17
]}

机构：

[1] Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China

[2] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China

[3] Jilin Prov Canc Hosp, Changchun, Jilin, Peoples R China

[4] Third Mil Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China

[5] Chungbuk Natl Univ Hosp, Chungcheongbuk Do, South Korea

[6] Kindai Univ Hosp, Osaka, Japan

[7] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[8] Sfj Pharma Japan KK, Osaka, Japan

[9] Germans Trias I Pujol Hlth Sci Inst, Catalan Inst Oncol, Barcelona, Spain

[10] Hosp Univ Virgen Del Rocio, Seville, Spain

[11] San Camillo Forlanini Hosp, Pulm Oncol Unit, Rome, Italy

[12] Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, Warsaw, Poland

[13] Sfj Pharmaceut Grp, Pleasanton, CA USA

[14] Pfizer Oncol, Collegeville, PA USA

[15] Pfizer Oncol, Groton, CT USA

[16] Pfizer Oncol, Shanghai, Peoples R China

[17] Chinese Univ Hong Kong, Hong Kong, Peoples R China

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期

关键词：

EGFR mutations; Dacomitinib; advanced non-small-cell lung cancer;

D O I：

10.1016/j.jtho.2017.09.347

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA 05.01

引用

页码：S1754 / S1754

页数：1

共 50 条

[21] Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and open issues [J].

Gridelli, C. ;

De Marinis, F. ;

Di Maio, M. ;

Cortinovis, D. ;

Cappuzzo, F. ;

Mok, T. .

LUNG CANCER, 2011, 72 (01) :3-8

[22] Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer [J].

Corral, Jesus ;

Mok, Tony S. ;

Nakagawa, Kazuhiko ;

Rosell, Rafael ;

Lee, Ki Hyeong ;

Migliorino, Maria Rita ;

Pluzanski, Adam ;

Linke, Rolf ;

Devgan, Geeta ;

Tan, Weiwei ;

Quinn, Susan ;

Wang, Tao ;

Wu, Yi-Long .

FUTURE ONCOLOGY, 2019, 15 (24) :2795-2805

[23] First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status [J].

Lee, Young Joo ;

Kim, Heung Tae ;

Han, Ji-Youn ;

Yun, Tak ;

Lee, Geon Kook ;

Kim, Hyae Young ;

Sung, Ji-Hyun ;

Lee, Jin Soo .

JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (03) :361-368

[24] First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations [J].

Kuwako, Tomohito ;

Imai, Hisao ;

Masuda, Tomomi ;

Miura, Yosuke ;

Seki, Kaori ;

Yoshino, Reiko ;

Kaira, Kyoichi ;

Utsugi, Mitsuyoshi ;

Shimizu, Kimihiro ;

Sunaga, Noriaki ;

Tomizawa, Yoshio ;

Ishihara, Shinichi ;

Ishizuka, Takao ;

Mogi, Akira ;

Hisada, Takeshi ;

Minato, Koichi ;

Takise, Atsushi ;

Saito, Ryusei ;

Yamada, Masanobu .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) :761-769

[25] The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer (EGFRm NSCLC) in Sweden [J].

Nilsson, Fredrik O. L. ;

Gal, Peter ;

Houisse, Ivan ;

Ivanova, Jasmina I. ;

Asanin, Sandra T. .

JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) :447-457

[26] First-Line Gefitinib for Patients With Advanced Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy [J].

Inoue, Akira ;

Kobayashi, Kunihiko ;

Usui, Kazuhiro ;

Maemondo, Makoto ;

Okinaga, Shoji ;

Mikami, Iwao ;

Ando, Masahiro ;

Yamazaki, Koichi ;

Saijo, Yasuo ;

Gemma, Akihiko ;

Miyazawa, Hitoshi ;

Tanaka, Tomoaki ;

Ikebuchi, Kenji ;

Nukiwa, Toshihiro ;

Morita, Satoshi ;

Hagiwara, Koichi .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1394-1400

[27] Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial [J].

Jaenne, Pasi A. ;

Ou, Sai-Hong I. ;

Kim, Dong-Wan ;

Oxnard, Geoffrey R. ;

Martins, Renato ;

Kris, Mark G. ;

Dunphy, Frank ;

Nishio, Makoto ;

O'Connell, Joseph ;

Paweletz, Cloud ;

Taylor, Ian ;

Zhang, Hui ;

Goldberg, Zelanna ;

Mok, Tony .

LANCET ONCOLOGY, 2014, 15 (13) :1433-1441

[28] Gefitinib for non-small-cell lung cancer treatment [J].

D'Incecco, Armida ;

Cappuzzo, Federico .

EXPERT OPINION ON DRUG SAFETY, 2011, 10 (06) :987-996

[29] Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung Cancer [J].

Hao, Xuezhi ;

Shen, Aizong ;

Wu, Bin .

FRONTIERS IN PHARMACOLOGY, 2021, 12

[30] Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in the Japanese population [J].

Nakagawa, Kazuhiko ;

Matsumura, Koichi ;

Scory, Tayler ;

Farris, Megan S. ;

Larkin-Kaiser, Kelly A. ;

Kikkawa, Hironori ;

Ivanova, Jasmina I. ;

Wilner, Keith D. .

FUTURE ONCOLOGY, 2021, 17 (01) :103-115

← 1 2 3 4 5 →